Some TRAEs were reported more frequently in the durvalumab plus tremelimumab cohort versus the durvalumab monotherapy cohort, including pruritus and rash, which is consistent with the literature where a higher incidence of AEs and high‐grade AEs are reported in anti‐PD‐1/PD‐L1 and anti‐CTLA‐4 combination therapies. Here, CTLA4 is linked to Pruritus.